Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May 15;7(6):3235-44.
eCollection 2014.

Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival

Affiliations

Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival

Jun Qin et al. Int J Clin Exp Pathol. .

Abstract

Although CD44 was overexpressed and considered as a useful prognostic marker in renal cell carcinoma, the prognostic role of CD44s in clear cell renal cell carcinoma (ccRCC) remains controversial. Moreover, the correlation and prognostic significance of CD44s and its downstream signaling target pSTAT3 are unclear in ccRCC. In this study, 75 pairs of carcinoma and paired adjacent non-tumor renal tissue samples were collected from patients with localized ccRCC who underwent a nephrectomy. The expression levels of CD44s and pSTAT3 were analyzed using immunohistochemistry. Correlations between CD44s/pSTAT3 expression and clinical and pathological characteristics were determined using x(2) test, Kaplan-Meier analysis and Cox's proportional hazards model. We found that CD44s is highly expressed in 46.67% of tumor tissues, and its high expression was significantly associated with high tumor grade (P < 0.001), large tumor size (P = 0.009) and advanced T stage (P = 0.004). A strong correlation exists between high expression of CD44s and pSTAT3 (r = 0.4013, P = 0.0004). The joint over expression of CD44s and pSTAT3 was present in 42.66% of tumor specimens and had an additive negative impact on overall survival. Patients with CD44s(high)pSTAT3(high) expression had significantly poor survival as compared to patients with CD44s(low)pSTAT3(low) tumor expression (P = 0.024), though the concurrent overexpression of CD44s and pSTAT3 was not an independent prognostic factor for overall survival. Our data indicate that expression of both CD44s and pSTAT3 in ccRCC is associated with advanced tumor stage and patient survival. The conclusions from this study may improve the prediction of ccRCC prognosis information when CD44s and pSTAT3 expression are evaluated together with classical clinicopathological parameters.

Keywords: CD44s; ccRCC; pSTAT3; prognosis; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative images of CD44s immunohistochemistry staining in clear cell renal cell carcinoma tissues. (A) Negative control, (B) non-neoplastic tissue, (C) no staining, (D) weak staining intensity, (E) intermediate staining intensity and (F) strong staining intensity. Bar, 101.3 μm. Magnification: 400X.
Figure 2
Figure 2
CD44s/pSTAT3 expression associated with patients’ overall survival. A: Kaplan-Meier analysis of overall survival in 43 patients comparing high and low CD44s expression groups. B: Kaplan-Meier analysis of overall survival in 43 patients comparing high and low pSTAT3 expression groups. C: Correlation analysis between CD44s and pSTAT3 expression in ccRCC patients. D: Kaplan-Meier analysis of overall survival for 43 patients based on CD44s and pSTAT3 expression. CD44shighpSTAT3high: patients with tumors overexpressing both proteins; CD44shigh or pSTAT3high: patients with tumors overexpressing only one of the two proteins; CD44slowpSTAT3low: patients with tumors low expressing both proteins.

References

    1. Jeong BJ, Liang ZL, Huang SM, Lim JS, Kim JM, Lee HJ. CD44 is associated with tumor recurrence and is an independent poor prognostic factor for patients with localized clear cell renal cell carcinoma after nephrectomy. Exp Ther Med. 2012;3:811–817. - PMC - PubMed
    1. Dutcher JP. Recent developments in the treatment of renal cell carcinoma. Ther Adv Urol. 2013;5:338–353. - PMC - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009;27:3584–3590. - PMC - PubMed
    1. Lim SD, Young AN, Paner GP, Amin MB. Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Arch. 2008;452:49–55. - PubMed
    1. Saroufim A, Messai Y, Hasmim M, Rioux N, Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone B, Escudier B, Chouaib S. Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. Br J Cancer. 2014;110:1778–1784. - PMC - PubMed

Publication types

MeSH terms